



MEDI LIFESTYLE LIMITED

(Company Registration Number 201117734D)
(Incorporated in the Republic of Singapore on 26 July 2011)

DISTRIBUTOR AGREEMENT WITH MALAYSIAN GENOMICS RESOURCE CENTRE BERHAD

PRESS RELEASE

The Board of Directors (the "Board" or "Directors") of Medi Lifestyle Limited (the "Company", and together with its subsidiaries, the "Group") is pleased to announce that the Company's indirect wholly owned subsidiary, HealthPro Marketing Sdn Bhd ("HPM") has signed a distributor agreement (the "Distributor Agreement") with Malaysian Genomics Resource Centre Berhad ("Malaysian Genomics"), for the Singapore and Cambodia markets, for marketing, sales and distribution of its cell and cell-free products including Mesenchymal Stem Cell-derived Exosomes ("Products"). The Distributor Agreement is valid for an initial 1 year and is renewable on an annual basis. HPM shall be granted exclusivity for the sales and distribution of the Products subject to certain targets being met.

Malaysian Genomics, a company listed on Bursa Malaysia, operates the only Bio-Safety Level 2 (BSL-2) laboratories in Southeast Asia that is Current Good Manufacturing Practice (cGMP)-approved for cell engineering BSL-2 and cGMP certifications indicate that a laboratory facility has stringent measures for biocontainment standards and ultra-pure laboratory environments to safely work on human cells.

Human umbilical cord-derived mesenchymal stem cells (UC-MSCs) are a class of cells with significant self-renewal and multi-lineage differentiation properties, and they are recognised for their therapeutic potential for anti-inflammation, cell regeneration and therapeutic effects against chronic diseases. UC-MSC-derived Exosomes contain valuable lipids, messenger-RNA, micro-RNA, signalling cytokines, and proteins. Exosomes are powerful elements that can restore cells throughout the human body. They enhance cell-to-cell communication, which is essential for overall cell health to stimulate healing. Exosome therapy is a highly targeted, flexible treatment for conditions like osteoarthritis, musculoskeletal injuries, chronic wound management, and skin regeneration.

Dato Ken Low, Executive Director & CEO of the Company, commented, "Our mission is to improve the quality of life for all. This is why we strive to provide excellent preventive healthcare and patient wellness services. By collaborating with Malaysian Genomics, we are now expanding our business growth into promoting and marketing cell and cell-free therapy products, this leads to continuous growth."

Dato' Alvin Nesakumar, Executive Director of Malaysian Genomics, said, "We are excited to have the opportunity to partner with HPM in providing products in support of their preventive health care services. Our laboratory facilities and expertise will be leveraged in this partnership."

The Distributor Agreement with MGRC is not expected to have an impact on the consolidated net tangible assets and earnings per share of the Group for the current financial year ending 31 December 2023.

Save for their shareholdings in the Company, none of the Directors or controlling shareholders of the Company has any interest, direct or indirect, in the Distributor Agreements. The Directors are also not aware of any substantial shareholders that have an interest, direct or indirect, in the Distributor Agreements.

Shareholders and other investors are reminded to exercise caution while dealing in the shares of the Company. In the event that shareholders and other investors are in doubt when dealing in the shares of the Company, they should consult their bankers, stockbrokers, solicitors or other professional advisers.

The Company will make the appropriate announcements as and when there are material developments.

By Order of the Board

Dato' Low Koon Poh
Executive Chairman and Chief Executive Officer
4 January 2023

MEDIA CONTACT

For media queries, please contact;

MEDI LIFESTYLE Limited
Corporate Communications Department
Tel: +65 6299 9881
Jeysie Wong (Mobile +60 13 257 2787, Email: jeysie.wong@medi-lifestyle.com)

This announcement has been reviewed by the Company's sponsor, SAC Capital Private Limited ("Sponsor"). This announcement has not been examined or approved by the Singapore Exchange Securities Trading Limited ("SGX-ST") and the SGX-ST assumes no responsibility for the contents of this announcement, including the correctness of any of the statements or opinions made, or reports contained in this announcement.

The contact person for the Sponsor is Ms Charmian Lim, at 1 Robinson Road, #21-00 AIA Tower, Singapore 048542, telephone: (65) 6232 3210.